Ivabradine in Cirrhotic Cardiomyopathy
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 153 people enrolled
- Started
- 1 Jan 2020
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Betablocker + ivabradine
- Betablocker
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (17)Hide the full registry criteria
Who can take part
- Age range of 18-65 years
- Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings,
- LV diastolic dysfunction on 2D echocardiography
Who cannot take part
- Chronic renal disease
- Hypertension
- Coronary artery disease
- Valvular heart disease
- Sick sinus syndrome/ Pacemaker
- Cardiac rhythm disorder
- Portal vein thrombosis
- Patient already on beta blocker
- Pregnancy and peripartum cardiomyopathy
- Hypothyroidism
- Hyperthyroidism
- Transjugular intrahepatic porto systemic shunt (TIPS) insertion
- Hepatocellular carcinoma
- Anemia Hb < 8gm/dl in females, and < 9 gm/dl in males
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
An anticipated total of 130 patients with liver cirrhosis who fulfill the criteria of the study, and who have been found to have left ventricular diastolic dysfunction on a screening 2D echocardiography, will then be randomized by Block randomization technique, to two arms in a ratio 1:1(Group A) will receive carvedilol+ Ivabradine targeted therapy for heart rate reduction while Group B will receive Carvedilol alone; and the dosage of drug in the treatment arm will be titrated every week to achieve target heart rate of 50-60/ minute. Patients in the treatment arms, who are unable to tolerate carvedilol due to hypotension episodes, will be offered ivabradine alone to allow achievement of targeted heart rate reduction. All patients will be evaluated at 0,6, and 12 months. The end points will be clinical events, cardiac function improvement, renal function, and mortality. An extended follow up till end of the study with echocardiographic and clinical follow up till 24 months after enrolment will be done.
The 2 groups in the trial
- Carvedilol + IvabradineTreatment being tested
Treatment: Betablocker + ivabradine
- CarvedilolExisting treatment, for comparison
Treatment: Betablocker
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Carvedilol + Ivabradine vs Carvedilol Alone for Left Ventricular Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality; a Prospective Randomized Controlled Trial.
- Record updated
- 17 November 2026